Table 7.
Role of ABC proteins in chemoresistance of colorectal carcinoma (CRC).
| Change | Drugs Affected | Impact | Ref. |
|---|---|---|---|
| MDR1 upregulation | Doxorubicin, vincristine | Decreased cell sensitivity in vitro | [174] |
| ABCB5 upregulation | 5-FU | Worse response | [176] |
| MRP1 upregulation | 5-FU, oxaliplatin | Decreased cell sensitivity in vitro | [177,178] |
| Irinotecan | Worse response | [179] | |
| MRP1 variant rs17501011 | 5-FU, irinotecan | Reduced OS | [180] |
| MRP2 upregulation | Cisplatin | Worse response | [181] |
| Cisplatin | Decreased cell sensitivity in vitro | [182] | |
| MRP3 upregulation | Etoposide, oxaliplatin | Decreased cell sensitivity in vitro | [183,184] |
| MRP4 variant rs3742106 | 5-FU | Worse response | [185] |
| MRP5 upregulation | 5-FU, doxorubicin, cisplatin, oxaliplatin | Decreased cell sensitivity in vitro | [104] |
| BCRP downregulation | 5-FU, oxaliplatin | Increased cell sensitivity in vitro | [186] |
5-FU, 5-Fluorouracil; BCRP, breast cancer resistance protein; MDR, multidrug resistance protein; MRP, multidrug resistant-associated protein; OS, overall survival.